IJERPH | Free Full-Text | Pharmacological Therapy of Non-Alcoholic Fatty Liver Disease: What Drugs Are Available Now and Future Perspectives | HTML
Aramchol attenuated lipid accumulation and ROS production in... | Download Scientific Diagram
Therapeutic pipeline in nonalcoholic steatohepatitis | Nature Reviews Gastroenterology & Hepatology
Key targets for drugs in phase 2 and phase 3 clinical trials. | Download Scientific Diagram
PBC NASH on Twitter: "ARREST: Phase IIb trial of aramchol in noncirrhotic patients with NASH is under way. #PBCNASH http://t.co/nESuRWVrrF" / Twitter
HCV-Trials.com : A regularly updated website with all most recent clinical trials data in HCV infection
Multicenter Trial png images | PNGWing
Development of new drugs for the treatment of nonalcoholic steatohepatitis - Tang - 2020 - Journal of Digestive Diseases - Wiley Online Library
HCV-Trials.com : A regularly updated website with all most recent clinical trials data in HCV infection
HCV-Trials.com : A regularly updated website with all most recent clinical trials data in HCV infection
The Fatty Acid–Bile Acid Conjugate Aramchol Reduces Liver Fat Content in Patients With Nonalcoholic Fatty Liver Disease - Clinical Gastroenterology and Hepatology
New Data on Aramchol TM for the Treatment of Non-alcoholic Steatohepatitis: Exploring Potential for Greater Efficacy and the Effect on Glucose Metabolism - European Medical Journal
One-year results of the Global Phase 2b randomized placebo-controlled ARREST Trial of Aramchol, a Stearoyl CoA Desaturasemodulator in NASH patients
Galmed And Aramchol In NASH: Moving On Higher (NASDAQ:GLMD) | Seeking Alpha
HCV-Trials.com : A regularly updated website with all most recent clinical trials data in HCV infection
The Fatty Acid–Bile Acid Conjugate Aramchol Reduces Liver Fat Content in Patients With Nonalcoholic Fatty Liver Disease - Clinical Gastroenterology and Hepatology
Diabetes & Metabolism Journal
FDA Agrees with Galmed's Plan to use Aramchol Meglumine in the Randomized Double-Blind Placebo-Controlled Part of the Phase 3 ARMOR study
Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial | Nature Medicine
Galmed: A Deep-Dive Analysis Of The ARREST Trial (NASDAQ:GLMD) | Seeking Alpha
The Armor Study - Armor
One-year results of the Global Phase 2b randomized placebo-controlled ARREST Trial of Aramchol, a Stearoyl CoA Desaturasemodulator in NASH patients
Identification of serum biomarkers associated with Aramchol treatment.... | Download Scientific Diagram
Aramchol™ reduces fibrosis progression in 24 weeks
Aramchol - Wikipedia
